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Acute myocardial infarction (AMI) is a major cause of
morbidity and mortality (1). It is estimated that around
30% of patients die within the first hour of the onset of
symptoms (2). In-hospital mortality rates approach 10%,
and an additional 10% of the survivors will die within the
first year after myocardial infarction.
Over the last two decades, a better understanding of
the blood coagulation and platelet function, the introduction of effective pharmacological agents, increased use of
coronary angiography, the development of advanced percutaneous techniques such as, percutaneous transluminal
coronary angioplasty (PTCA), and coronary stenting have
made a dramatic change in the acute management of
myocardial infarction. Fortunately, there has been a
steady decline in the mortality rates following myocardial
infarction during the same period.
Almost a century ago, Herrick postulated that the
triggering event of myocardial infarction was coronary
thrombosis (3). Herrick’s hypothesis was proven by
angiographic studies demonstrating that total occlusion
of the coronary artery by a thrombus was present in 87%
of AMI patients evaluated within 4 hours of symptom
onset (4). Recent studies have elucidated a cascade of
events leading to coronary artery occlusion by a thrombus. There is a disruption of endothelial barrier after atherosclerotic plaque rupture with exposure of subendothelial matrix and activation of the cellular components of the
plaque which results in platelet activation, thrombus formation and finally coronary occlusion (5-8). Pathology
studies after myocardial infarction (MI) and sudden
ischemic cardiac death, showed layers of platelet thrombi
in different stages of organization at the site of coronary
occlusion supporting this theory (7, 9).
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Nearly 80 years later, a better understanding of
Herrick’s initial vision made emergent reperfusion therapy, either pharmacological or catheter based, the goal in
the treatment of myocardial infarction. We will try to
summarize new strategies to quickly achieve this cardinal
goal in the clinical setting.
New Concepts in Pharmacotherapy
Advances in Thrombolytic Therapy
The usual cause of MI in humans is an occlusive
thrombus in the coronary artery (3). Over the last
decade, the effective use of thrombolytic therapy has
started a new era in the treatment of this major cause of
morbidity and mortality. The therapeutic benefits of
aspirin and/or thrombolytic agents after myocardial
infarction support the critical role of platelets and thrombus formation. Activating plasminogen by thrombolytic
agents in patients with MI dissolves the fibrin elements of
the thrombus and reestablishes the coronary patency
(10). Thrombolytic therapy has greatly improved the
prognosis of patients with AMI by rapid recanalization of
the infarct related artery (11-13). Large scale studies
revealed that the early administration of thrombolytic
agents was associated with significant reduction in mortality (10-13).
Large, multi-center trials have confirmed 18 to 47%
mortality reduction in AMI after treatment with thrombolytic agents streptokinase (SK) (11), recombinant tissue plasminogen activator (rtPA or activase) (12), panisoylated plasminogen streptokinase activator complex
(APSAC or anistreplase) (13).
New thrombolytic agents are being investigated with
studies comparing them to rtPA or SK. Reteplase (rPA),
threonine-asparagine-lysine (TNK), lanoteplase (nPA) are
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derivatives tPA molecule. Activase has a short half life
requiring continuos intravenous infusion to achieve therapeutic levels. Alterations in the molecular structure of
rtPA provided longer half lives allowing the new agents to
be administered by single intravenous bolus injection.
Furthermore, structural changes of TNK and nPA created
an increased fibrin specificity and effectiveness on platelet
rich thrombi.
GUSTO-3 (Global Use of Strategies to Open Coronary
Arteries trial) compared the new agent rPA and the wild
type rtPA which is produced by using recombinant DNA
technology using Escherichia Coli (14). Similar 24 hour,
in-hospital, and 30 day mortality were reported with
comparable incidences of bleeding complications. TIMI-10
and InTIME trials showed promising results with the new
agents TNK and nPA respectively (15, 16).
Prourokinase (also known as saruplase or scuPA),
staphylokinase, vampire bat salivary plasminogen activator are other new thrombolytic agents which demonstrated promising results in the preliminary studies (17,
18). Prourokinase is a naturally occurring human protein
which is the precursor to urokinase. PRIMI (Prourokinase
in Myocardial Infarction) trial compared scuPA to SK in
MI patients presenting within 6 hours of symptom onset
(17). scuPA resulted in higher rates of patent infarct
related artery and fewer bleeding complications.
Staphylokinase is a 136 amino-acid protein produced
by Staphylococcus Aureus. It can activate plasminogen. A
small clinical trial revealed similar infarct related artery
patency rates to rtPA (18).
Evidence from such trials leaves no doubt that time to
treatment is the most important parameter in myocardial
reperfusion (10-13). Patients treated in the first hour
have the highest mortality benefit (19,20). The development of these new agents has started a new concept of
"bolus thrombolysis", permitting administration of the
thrombolytic agent as a single bolus. The simplicity of
dosing may provide more rapid treatment of AMI patients
and potentially improve the survival. Importantly, bolus
thrombolysis may make the promising strategy of prehospital treatment of AMI more feasible (21).
Advances in Antiplatelet Therapy
Aspirin provided substantial mortality benefit in
patients with AMI. A multicenter, multinational study, the
Second International Study of Infarct Survival (ISIS-2)
randomized 17.187 patients with acute myocardial
infarction to receive 162.5 mg of oral aspirin daily for
one month, or placebo (11). At 35 days, there were statistically significant reductions in vascular mortality
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(23%) and reinfarction (55%) in the group receiving
aspirin (11). Since this trial, the use of aspirin has become
a cornerstone of therapy for patients with AMI. The recommended dose is 325 mg per day and it is continued
indefinitely.
Despite the indisputable benefit with aspirin after AMI
many patients have recurrent ischemic events even on
aspirin therapy (22). Furthermore, an initially successful
response to thrombolytic therapy may be offset by reocclusion (23). This has stimulated the search for the ideal
adjunctive agent in attempts to inhibit the coronary
thrombus formation.
The development and availability of the GPIIb/IIIa
inhibitors has initiated a new era in our approach to
myocardial infarction. Several studies are assessing the
safety and usefulness of these compounds in the setting
of acute myocardial infarction.
The success of thrombolytic therapy stems from its
ability to activate plasminogen, lyse the occlusive thrombus, and restore the blood flow in 70% of the infarct
related arteries (24). However, about 30% of occluded
infarct related arteries still cannot be reperfused even
with the best thrombolytic therapy regimen. Additionally,
in the initial trials assessing available thrombolytic therapy, the incidence of coronary occlusion from rethrombosis was approximately 20%, and the incidence of reinfarction was 10% (25). Most of these occlusions
occurred in the first 24 hour. One plausible cause of
resistance to plasminogen activators or thrombolytic
therapy is the presence of platelet-rich thrombus.
Platelets are the richest source of circulating plasminogen
activator inhibitor (PAI-1), hence can readily inactivate
exogenously given plasminogen activators (such as tPA or
streptokinase). Patients who undergo coronary thrombolysis with either streptokinase (26) or t-PA (27) exhibit an increase in their urinary excretion of metabolites of
thromboxane, consistent with the activation of platelets
by these thrombolytic agents.
There is strong clinical and experimental evidence supporting the pivotal role of antiplatelet therapy in treatment of AMI. The therapeutic benefit of combined
antithrombotic therapy was strongly demonstrated in the
ISIS-2 study, where the combination resulted in a doubling in the reduction of mortality that was observed in
patients treated with either aspirin or streptokinase alone
(11).
In a chronic, canine model of coronary thrombosis,
Fitzgerald et al. demonstrated that tPA 10 µg/kg/min
induced reperfusion in 55±7 minutes, but complete reocclusion occurred in 9/10 animals. Reocclusion was pre-
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vented by combining plasminogen activating effects of
tPA with antiplatelet effects of a GP IIb/IIIa inhibitor
(c7E3, a genetically engineered chimeric monoclonal antibody that can inhibit GP IIb/IIIa receptor permanently)
(28). In an another experimental model, c7E3 Fab antibody suppressed the expression of PAI-1 by cultured
microvascular cells (29), therefore this antibody may have
a beneficial effect on the fibrinolytic balance of t-PA/PAI-1
along with the well known anti-platelet effects.
Therefore, the use of GPIIb/IIIa inhibitors along with
thrombolytic therapy may potentially provide improved
infarct vessel patency, reduced vessel closure, and reinfarction. Another animal study by Garabedian et al. studied the ability of a peptide inhibitor of GP IIb/IIIa, eptifibatide, to accelerate endogenous fibrinolysis in a canine
model. They compared fibrinolytic effects of eptifibatide
and tPA. With heparin and aspirin, eptifibatide restored
coronary blood flow with equal frequency to tPA (30).
In addition to the experimental and animal data supporting the use of these receptors in AMI, in the clinical
setting Gold et al. administered an irreversible inhibitor of
GP IIb/IIIa receptor, c7E3 Fab to patients who had angiographic occlusion of infarct related artery after acute
anterior myocardial infarction (31). GPIIb/IIIa blockade
resulted in normal blood flow at the infarct related artery
without any further intervention in 7 out of 13 patients.
Despite the evidence supporting the important role of
antiplatelet therapy as an adjunct to fibrinolysis, the trials
of GP IIb/IIIa inhibitors in the setting of AMI have lagged
behind their use for unstable angina and/or after percutaneous coronary intervention. RAPPORT trial (ReoPro in
Acute Myocardial Infarction Primary PTCA Organization
and Randomized trial) randomly assigned 483 patients to
a bolus and 12 hour infusion of abciximab versus placebo
during primary angioplasty (32). Composite endpoints of
death, myocardial infarction and urgent repeat revascularization were reduced in the abciximab arm at 7 days
(8.3% vs 3.3%, p=0.015), however there was no difference between the groups at 6 months.
PARADIGM (Platelet Aggregation Receptor Antagonist
Dose Investigation for Reperfusion Gain in Myocardial
Infarction) trial evaluated the use of competitive, nonpeptide inhibitor lamifiban in combination with thrombolysis after AMI (33). Patients with ST segment elevation
presenting within 12 hour of symptom onset treated with
either SK or tPA were enrolled in this Phase II study. A
composite of angiographic, continous electrocardiographic and clinical markers of reperfusion was the primary end
point. ECG monitoring demonstrated significantly
enhanced reperfusion in patients treated with lamifiban.
Small number of patients (34 patients) underwent elec-

tive 90 minute cardiac catheterization, and no effect was
seen on early TIMI 3 flow. Excess bleeding was noted in
lamifiban treated patients (transfusions in 16.1 of lamifiban treated patients vs. 10.3% placebo treated
patients).
TIMI-14 trial compared thrombolytic therapy with
tPA, and three different combinations of reduced dose
tPA plus a non-competitive GP IIb/IIIa receptor inhibitor,
abciximab, in approximately 900 patients presenting with
myocardial infarction. The primary endpoint of the study
the rate of TIMI-3 flow at 60 and 90 minutes. Patients in
the abciximab arm received only 50 mg of tPA compared
to standard dose of 100 mg. At 60 minutes 43% of
patients in the tPA-only arm achieved TIMI-3 flow compared to 77% in the tPA plus abciximab arm (34). Similar
pattern was noted at 90 minutes.
ASSENT-II, HERO-II, SPEED, GUSTO 4, APPLAUD,
SYMPHONY are some of the other large scale studies that
will prospectively assess these novel agents in the setting
of acute myocardial infarction (35).
New Concepts in Catheter Based Therapy
Recognition of the thrombotic occlusion caused a dramatic change in the management of patients with AMI.
Emergent reperfusion therapy became the cardinal goal in
the treatment of myocardial infarction. Timely given
thrombolytic therapy has a life saving benefit in these
patients, however only about 50% of patients with AMI
are eligible for thrombolytic treatment (36).
Angiographic substudy of GUSTO trial demonstrated
another limitation of the thrombolytic therapy. Wide differences exist in the patency of infarct related artery after
administration of various thrombolytic regimens. Even
the most aggressive thrombolytic regimen with front
loaded tPA restored normal angiographic blood flow
(TIMI grade 3 flow as defined in the Thrombolysis in
Myocardial Infarction trial) in only 54% of patients (23).
Additionally, in the initial trials assessing available
thrombolytic therapy, the incidence of coronary occlusion
from rethrombosis was approximately 20%, and the incidence of reinfarction was 10% (25). Most of these occlusions occurred in the first 24 hour.
The shortcomings of thrombolytic treatment fueled a
number of randomized trials comparing pharmacotherapy and catheter based therapy as an initial strategy for
reperfusion. These trials differ in the designs with respect
to the thrombolytic agent, dosing, dose and duration of
heparin, the time window form symptom onset to the
enrollment and finally the endpoints.
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GUSTO 2B trial randomized 1138 patients within 12
hours of myocardial infarction to intravenous thrombolytic therapy versus direct angioplasty (37). The primary endpoints of the trial were death, non-fatal MI, and
disabling stroke at 30 days. TIMI 3 flow rate was 73 to
88% in the angioplasty group. The angioplasty group did
better at 30 days (composite endpoints of 9.6% vs
13.7%, p=0.033). The benefit was not long-lasting
however, at 6 months there was no difference in the composite endpoints (14.1% vs 16.1). One of the reasons for
the lack of the difference might be lesser success rates of
TIMI 3 flow with PTCA than previously reported.
Several other trials have been conducted to investigate
the outcomes of myocardial reperfusion achieved by
emergency percutaneous transluminal coronary angioplasty (PTCA) vs thrombolytic therapy. In an effort to
answer this important question, a recent meta-analysis of
10 randomized trials involving over 2600 patients compared 30 day mortality and stroke rates between the two
strategies (38). Thirty day mortality was 4.4% for 1290
primary angioplasty patients versus 6.5% for 1316
thrombolytic patients (34% risk reduction). Lower stroke
rate was reported with angioplasty (0.7% versus 2.0%;
p=0.007) .
We have to mention that while thrombolytic therapy
can be applied in most of the hospitals, the majority of
patients with AMI do not have access to facilities in which
emergency PTCA can be performed timely and safely.
Furthermore, the benefit with primary angioplasty was
possible with the experienced operators of the enrolling
centers. Therefore, American College of Cardiology
(ACC)/American Heart Association (AHA) guidelines clearly outlined the class I indication for primary PTCA in
U.S.A. : "As an alternative to thrombolytic therapy only if
performed in a timely fashion by individuals skilled in the
procedure and supported by experienced personnel in
high volume centers."(39).
Given the change in the catheter based reperfusion
adding stents and new adjunctive treatment such as GP
IIb/IIIa inhibitors, it is likely that there will not be similar
trials of "plain old balloon angioplasty" vs thrombolytic
treatment in future.
In the interest of space, we will not get into the other
indications of PTCA after MI, such as "rescue" PTCA after
thrombolytic therapy or elective PTCA after MI. The
Plasminogen-activator Angioplasty Compatibility Trial
(PACT) trial compared two different strategies: rescue
PTCA versus primary PTCA (40). The trial was designed
to compare ventricular function outcome in patients ran-
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domized to PTCA versus thrombolysis plus PTCA for AMI.
Delay in time to successful reperfusion (TIMI 3) resulted
in significant loss of myocardium. Thus, combining different strategies of reperfusion such as thrombolytic treatment and primary PTCA may decrease delay to TIMI 3
flow, hence improve the outcome.
Stenting in Acute Myocardial Infarction
Stenting was initially considered to be contraindicated
after acute myocardial infarction with the fear stent
thrombosis. However, recent progress in the prevention
of this problem with antiplatelet agents made stenting a
acceptable approach to improve the results of primary
angioplasty. The recent PAMI-stent (Primary Angioplasty
in MI) trial randomized 900 patients to stent (using
heparin coated Palmaz-Schatz stent) versus PTCA.
Preliminary results demonstrate a similar acute angiographic success between the two groups with no statistical outcome difference at one month with the exception
of reduced ischemia driven target vessel revascularization
(TVR) in the stent group (41). These findings are similar
to the recently presented GRAMI trial (42). In this smaller study of 104 patients with AMI, 52 patients had primary PTCA without stenting and the other half underwent a GR II stent placement. The in-hospital major
adverse clinical events were reduced in the stent arm
(19.2% vs 3.8%). At one year follow-up, the TVR rate
was lower in the stent arm without reaching statistical
difference (9.6% vs. 13.4%). We need further studies
with longer follow-up to assess the role of stenting in
AMI.
Conclusion
Over the past two decades, several therapies with
proven benefit have become available to improve the outcome of a patient with AMI. Science has provided new
options in fibrinolytic therapy (anistreplase, TNK-tPA, and
lanetoplase), antithrombin therapy (different types of low
molecular weight heparin and direct thrombin inhibitors),
and antiplatelet therapy (GP IIb/IIIa inhibitors, clopiogrel).
This remarkable progress in pharmacotherapy is accompanied by novel concepts in catheter based therapy of
AMI. How we combine these strategies effectively in different clinical settings remains to be answered. One can
come up with an enormous number of combinations
using different regimens at different doses, coupling with
different catheter based interventions. We hope future
experience and efforts will teach us rational ways of making choices.

M. AGİRBASLİ, S.B. KİNG

References
1.

Graves EJ. Detailed diagnoses and procedures: National Hospital Discharge
Survey , 1990. National Center for
Health Statistics. Vital Health Stat {13}.
1992; 113.

2.

McNeilly RH, Pemberton J. Duration of
last attack in 998 fatal cases of coronary artery disease and its relation to
possible cardiac resuscitation. Br Med J
1968; 3: 139.

3.

4.

5.

Herrick JB. Clinical features of sudden
obstruction of the coronary arteries.
JAMA 1912; 59: 2015.
DeWood MA, Spores J, Notske R,
Mouser LT, Burroughs R, Golden MS,
Lang HT. Prevalence of total coronary
occlusion during early hours of transmural myocardial infarction. N Eng J
Med 1980; 303: 897.

9.

Davies MJ, Thomas AC, Knapman PA,
Hangartner JR. Intramyocardial platelet
aggregation in patients with unstable
angina suffering sudden ischemic cardiac death. Circulation 1986; 73: 417427.

10.

Yusuf S, Collins R, Peto R. Intravenous
and intracoronary fibrinolytic therapy in
acute myocardial infarction: Overview
of results on mortality, reinfarction and
side effects from 33 randomized control trials. Eur H J 1985; 6: 556.

11.

ISIS-2
Collaborative
Group.
Randomized trial of intravenous streptokinase, oral aspirin, or both, or neither among 17.187 cases of suspected
acute myocardial infarction. Lancet
1988; II: 349-360.

12.

Alexander RW. Hurst’s The Heart (8th
Edition). The coronary ischemic syndromes: Relationship to the biology of
atherosclerosis. 1994; 1021.

6.

7.

8.

Ambrose JA, Winters SL, Stern A, Eng
A, Teicholz LE, Gorlin R, Fuster V.
Angiographic morphology and the
pathogenesis of unstable angina pectoris. J Am Coll Cardiol. 1985; 5: 609616.
Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis
leading to infarction and/or sudden
death: autopsy evidence of recurrent
mural thrombosis with peripheral
embolization culminating in total vascular occlusion. Circulation 1985; 71:
699-708.

13.

14.

15.

Hirsch PD, Hillis LD, Campbell WB,
Firth BG, Willerson JT. Release of
prostaglandins and thromboxane into
the coronary circulation in patients with
ischemic heart disease. N Eng J Med.
1981; 304: 685-691.
16.

Wilcox RG, von der Lippe G, Olsson
CG, Jensen G, Skene AM, Hampton R.
Trial of tissue plasminogen activator for
mortality reduction in acute myocardial
infarction: Anglo-Scandinavian Study of
Early Thrombolysis (ASSET) Lancet
1988; 2: 525-530.
AIMS Trial Study Group. Long term
effects of intravenous anistreplase in
acute myocardial infarction: final report
of the AIMS Study. Lancet 1990; 335:
427-431.
The Global Use of Strategies to Open
Occluded Arteries (GUSTO III)
Investigators. A comparison of
reteplase with alteplase for acute
myocardial infarction. N Eng J Med
1997; 337: 1118-1123.
Cannon C, McCabe CH, Gibson CM,
Ghali M, Sequeira RF, McKendall GR,
Breed J, Modi NB, Fox NL, Tracy RP,
Love TW, Braunwald E. TNK tissue
plasminogen activator in acute myocardial infarction (TIMI) 10A dose-ranging
trial. Circulation 1997; 95: 351-356.
Thadani U. Treatment of Infarcting
Myocardium Early (InTIME) [Abstract]
ACC 1997.

17.

Meyer J, Bar FW, Barth H. Randomized
double blind trial of recombinant prourokinase against streptokinase in
acute myocardial infarction. Lancet
1989; 1: 863-868.

18.

Vanderschueren S, Dens J, Kerdsinchai
P, Desmet W, Vrolix M, DeMon F, Van
den Huevel P, Hermans L, Collen D,
Van de Werf F. Randomized coronary
trial of double-bolus staphylokinase
versus front-loaded alteplase in acute
myocardial infarction. Am Heart J.
1997; 134: 213-219.

19.

Lincoff AM, Topol EJ. The illusion of
reperfusion. Does anyone achieve optimal reperfusion? Circulation 1993; 87:
1792-1805.

20.

Boersma E, Maas AC, Deckers JW,
Simoons ML. Early thrombolytic treatment in acute myocardial infarction:
Repraisal of the golden hour. Lancet
1996; 348: 771-775.

21.

The European Myocardial Infarction
Project Group. Prehospital thrombolytic therapy in patients with suspected
acute myocardial infarction. N Eng J
Med 1993; 329: 383-389.

22.

Buchanan MR, Brister SJ. Individual
variation in the effects of ASA on
platelet function: implications for the
use of aspirin clinically. Can J Cardiol.
1995; 11: 221-227.

23.

The GUSTO Angiographic Investigators.
The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. N Eng J Med 1993;
329: 1615-1622.

24.

Chesebro J, Knatterud G, Braunwald E.
Thrombolytic therapy (letter). N Eng J
Med 1988; 71: 627-631.

25.

Roberts R. Thrombolysis and its sequelae: Calcium antagonists as potential
adjunctive therapy. Circulation 1989;
80(IV): 93-101.

605

New Frontiers in The Reperfusion of Myocardial Infarction

26.

Kerins DM, Roy L, Fitzgerald GA,
Fitzgerald DJ. Platelet and vascular
function during coronary thrombolysis
with tissue-type plasminogen activator.
Circulation 1989; 80: 1718-1725.

27.

Fitzgerald DJ, Catalla F, Roy L,
Fitzgerald GA. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial
infarction. Circulation 1988; 77: 142150.

28.

29.

30.

31.

32.

606

Fitzgerald DJ, Hanson M, Fitzgerald
GA. Systemic lysis protects against the
effects of platelet activation during
coronary thrombolyis. J Clin Invest
1991; 88: 1589-1595.
Shatos MA, Doherty JM, Garabedian
HD, Gold HK. Reopro, antiplatelet antibody, enhances fibrinolytic potential of
cultured arterial microvascular cells.
Circulation 1996; 94: I-702[Abstract].
Garabedian HD, Guerrero JL,
Hollenbach S, Homcy C, Leinbach RC,
Gold HK. Comparative efficacy of intravenous eptifibatide, a potent and
reversible platelet GP IIb/IIIa receptor
antagonist, versus recombinant tissue
plasminogen activator for coronary
thrombolysis in a canine model.
Circulation 1998; 98:I-561 [Abstract].
Gold HK, Garabedian HD, Dinsmore
RE, Guerrero LJ, Cigarroa JE, Palacios
IF, Leinbach RC. Restoration of coronary flow in myocardial infarction by
intravenous chimeric 7E3 antibody
without exogenous plasminogen activators. Circulation 1997; 95: 17551759.
Brener S, Barr LA, Burchenal JE, Katz
S, George BS, Jones AA, Cohen ED,
Gainey PC, White HJ, Cheek HB,
Moses JW, Moliterno DJ, Effron MB,
Topol EJ. Randomized placebo controlled trial of glycoprotein IIb/IIIa
blockade with primary angioplasty for
acute MI. ReoPro and Primary PTCA
Organization and Randomized Trial
(RAPPORT) Investigators. Circulation
1998; 98: 734-741.

33.

The
PARADIGM
Investigators.
Combining thrombolysis with the
platelet glycoprotein IIb/IIIa inhibitor
lamifiban: Results of the platelet aggregation receptor antagonist dose investigation and reperfusion gain in myocardial infarction (PARADIGM) trial. J Am
Coll Cardiol 1998; 32: 2003-2010.

34.

Giugliano RP, Antman EM, McCabe
CH, Anderson KM, Adgey AAJ, Kleiman
NS, Ghali M, Van de Werf F, Braunwald
E. Abciximab + tPA improves coronary
flow in a wide range of subgroups:
Results from TIMI 14. Circulation
1998; 98:I-560 [Abstract].

35.

Tcheng JE. Platelet integrin glycoprotein IIb/IIIa inhibitors: opportunities and
challenges. J Invas. Cardiol 1996; 8:
8B-14B.

36.

Ellis CJ, French JK, Williams BF, Wyatt
S, Poole J, Ingram C. Thrombolytic
therapy can be given to half of hospitalized patients with acute myocardial
infarction [abstract]. J Am Coll Cardiol
1996; 27: 249A.

37.

The GUSTO IIb Angioplasty Substudy
Investigators. A clinical trial comparing
primary coronary angioplasty with tissue plasminogen activator for acute
myocardial infarction. N Eng J Med
1997; 336: 1621-1628.

38.

Weaver WD, Simes RJ, Betriu A, Grines
CL, Ziljstra F, Garcia E, Grinfeld L,
Gibbons RJ, Riberio EE, DeWood MA,
Ribichini F. Comparison of primary
angioplasty and intravenous thrombolytic therapy for acute myocardial
infarction. JAMA 1997; 278: 20932098.

39.

Ryan TJ, Anderson JL, Antman EM,
Braniff BA, Brooks NH, Califf RM, Hillis
LD, Hiratzka LF, Rappaport E, Riegel
BJ, Russell RO, Smith EE, Weaver WD.
ACC/AHA Guidelines for the management of patients with acute myocardial
infarction:
Executive
summary.
Circulation 1996; 94: 2341-2350.

40.

Lundergan CF, Reiner JS, Coyne CS,
Fink C, Frey AJ, Racine N, Ross AM.
Effect of delay of successful reperfusion
on ventricular function outcome: The
case for prior thrombolytic therapy
with PTCA in acute myocardial infarction. Circulation 1998; 98:I-281.

41.

Grines CL, Cox DA, Garcia E, Stone G,
Mattos L, Katz S, Giambartolomei AA,
Brodie B, Donohue B, Madonna O,
O’Neill WW, Claude-Maurice M. StentPAMI: Primary endpoint results of a
multicenter randomized trial of heparin
coated stenting vs primary PTCA for
AMI [Abstract]. Circulation 1998; 98:I22.

42.

Rodriguez AE, Bernardi VH, Santeara
OA, Mauvecin C Ayala F, Martinez J,
Roubin GS, Palacios IF, Ambrose JA.
Coronary stents improve outcome in
acute myocardial infarction: Immediate
and long term results of the GRAMI trial
[Abstract]. J Am Coll Cardiol 1998; 31:
64A.

